

## BK polyomavirus in Kidney transplant recipients: screening, monitoring and clinical management

BK poliomavírus em receptores do transplante renal: rastreamento, monitoramento viral e manuseio clínico

### Autores

Rafael Brandão Varella<sup>1</sup>  
 Jorge Reis Almeida<sup>1</sup>  
 Patrícia de Fátima Lopes<sup>1</sup>  
 Jorge Paulo Strogoff de Matos<sup>1</sup>  
 Paulo Menezes<sup>1</sup>  
 Jocemir Ronaldo Lugon<sup>1</sup>

<sup>1</sup> Fluminense Federal University (UFF).

Data de submissão: 13/02/2014.  
 Data de aprovação: 22/05/2014.

**Correspondência para:**  
 Rafael Brandão Varella.  
 Laboratory of Virology,  
 Department of Microbiology  
 and Parasitology - Universidade  
 Federal Fluminense.  
 Rua Ernani Pires de Melo, nº 101,  
 Niterói, RJ, Brasil. CEP: 24210-130.  
 E-mail: rvarella@id.uff.br  
 FAPERJ (Processo:  
 E-26/111.225/2013).

DOI: 10.5935/0101-2800.20140075

### ABSTRACT

BK polyomavirus (BKPyV) is a causal agent of nephropathy, ureteral stenosis and hemorrhagic cystitis in kidney transplant recipients, and is considered an important emerging disease in transplantation. Regular screening for BKPyV reactivation mainly during the first 2 years posttransplant, with subsequent pre-emptive reduction of immunosuppression is considered the best option to avoid disease progression, since successful clearance or reduction of viremia is achieved in the vast majority of patients within 6 months. The use of drugs with antiviral properties for patients with persistent viremia has been attempted despite unclear benefits. Clinical manifestations of BKPyV nephropathy, current strategies for diagnosis and monitoring of BKPyV infection, management of immunosuppressive regimen after detection of BKPyV reactivation and the use of antiviral drugs are discussed in this review.

**Keywords:** infection control; kidney transplantation; monitoring; review.

### RESUMO

BK Poliomavírus (BKPyV) é um agente causal de nefropatia, estenose ureteral e cistite hemorrágica em receptores de transplante renal, sendo considerado uma importante doença emergente na transplantação. Rastreamento regular para reativação do BKPyV, principalmente nos dois primeiros anos pós-transplante, com subsequente redução preemptiva da imunossupressão é considerada a melhor conduta para evitar a progressão da doença, já que a eliminação ou redução da viremia é alcançada na grande maioria dos pacientes dentro de 6 meses. O uso de drogas com propriedades antivirais para os pacientes com viremia persistente tem sido tentado, embora sem benefícios claros. As manifestações clínicas da nefropatia por BKPyV, as estratégias para o diagnóstico e monitoramento da infecção por BKPyV, o manejo do regime de imunossupressão após a detecção da reativação do BKPyV e o uso de drogas antivirais são discutidas nesta revisão.

**Palavras-chave:** controle de infecções; monitoramento; revisão; transplante de rim.

### INTRODUCTION

BK polyomavirus (BKPyV) belongs to the family *Polyomaviridae* (former *Papovaviridae*) and are small (45-50 nm), nonenveloped virus with an icosahedral capsid and a core of circular double-stranded DNA in association with histones.<sup>1,2</sup> The virus was first isolated in 1971 and named after the initials of a Sudanese transplant recipient with ureteral stenosis.<sup>3</sup>

BKPyV is subdivided into four subtypes/serotypes: I, II, III, and IV. The geographic distribution of the

subtypes suggests a close relationship between BKPyV and migration of human populations, although without any apparent clinical significance.<sup>4,5</sup>

BKPyV is ubiquitous in human population.<sup>6</sup> Primary infection occurs in the first decade of life as evidenced by increases in BKPyV seroprevalence to 90% and more.<sup>7</sup> Natural BKPyV transmission is not clear, but likely occurs via the respiratory or oral route. Primary infection in healthy children is usually asymptomatic, but may manifest as a common cold.<sup>8</sup> After primary viremia, the

virus establishes a latent phase, persisting indefinitely in different tissues, especially the urinary tract.<sup>2,9</sup>

In approximately 5% to 10% of healthy individuals, BKPyV reactivates with variations in immune status and gives asymptomatic low-level urinary shedding.<sup>10</sup> However, no histopathological changes are observed in the kidney parenchyma, and renal function is left unaffected.<sup>1</sup>

## CLINICAL MANIFESTATIONS

Replication of BKPyV occurs during states of immune suppression. Viruria occurs in pregnancy, cancer, HIV infection, diabetes, and transplantation. However, viremia and BKPyV nephropathy (BKVN) are rare outside of kidney transplantation.<sup>11</sup> Apart from immune status, other variables such as older age, male gender, white ethnicity, diabetes, BKPyV seronegativity prior to transplantation, immunosuppressive drug regimen, ischemic lesion during transplantation and viral mutations, are considered risk factors for BK disease.<sup>12</sup>

BKPyV infections in immunosuppressed individuals can lead to distinctive pathological entities in different patient groups: in renal transplant recipients, it is associated with nephropathy and ureteral stenosis, whereas in hematopoietic stem cell transplant (HSCT) recipients with hemorrhagic cystitis.<sup>2,8,12</sup>

BKVN is the result of viral replication in renal tissue, and is characterized by a histologically manifest renal allograft infection with BKPyV and deteriorating graft function. The gold standard for BKVN is still a renal biopsy.<sup>10</sup> Since it has a patchy distribution affecting mostly the renal medulla,<sup>13</sup> two core biopsy samples including medulla should be obtained in order to confirm the BKPyV presence by *in situ* hybridization or immunohistochemistry for anti-SV40 or large T.<sup>12</sup> The histologic patterns of BKVN have been divided into three types, being characterized by the presence of nuclear inclusions (Type A), acute inflammation with little chronic fibrosis (Type B), and significant chronic fibrosis and atrophy (Type C).<sup>14</sup> In 25-40% of the patients experiencing high level viruria/decoy cell positivity will develop viremia, and in the absence of intervention, progression to BKVN may occur.<sup>10</sup> The prevalence of BKVN may vary from center to center, but generally ranges from 1% to 10% and

the result is the graft loss in up to 80% of cases.<sup>12,15</sup> Its noteworthy that nephropathy can also be caused by another polyomavirus named JC in rare cases, which demands additional investigation in the event of nephropathy without BKPyV detection.<sup>16</sup>

Hemorrhagic cystitis (HC) is the most common BKPyV manifestation of genitourinary infection in HSCT recipients. The virally induced form of HC usually occurs after engraftment and is therefore referred to as late-onset hemorrhagic cystitis, which occurs in 6 to 29% of HSCT patients, generally within the first two months after transplantation. Patients present with hematuria, painful voiding, bladder cramps, and/or flank pain.<sup>3</sup>


The ureteral stenosis occurs in approximately 3% (2-6% range) of renal transplant patients and generally develops several months after transplantation.<sup>3</sup> The virus may exert a direct cytopathic effect on the ureteral epithelium, resulting in ulceration and inflammation, which leads to obstructive uropathy.<sup>17</sup>

In addition, BKPyV is also possibly related to pneumonia, encephalitis and several types of cancer.<sup>18</sup> These non-urinary BKPyV-induced diseases are not surprising at all given the viral persistence in different human tissues and the oncogenic potential of polyomaviruses.<sup>19,20</sup>

## METHODS FOR BKPYV SCREENING IN URINE AND BLOOD

The methods used to detect and quantify BKPyV are based on the pathogenesis of the infection.<sup>11</sup> Viral replication begins early after transplantation and progresses through detectable stages: viruria to viremia and then to nephropathy (Figure 1). The onset for each event is variable: viruria is usually reported  $\geq$  5 weeks after transplantation, followed by viremia after 4-5 weeks,<sup>21,22</sup> which in turn precedes BKVN in 8-12 weeks.<sup>23,24</sup>

**Figure 1.** BKPyV events following renal transplantation. \* Adapted from reference 11.



In general, viruria-based methods are considered valuable tools for BKPyV screening (high negative predictive value, NPV) but weakly indicative of kidney or urinary tract diseases (low positive predictive value, PPV), since less than a half of all patients with viruria will progress to the viremia stage.<sup>25</sup> Three methods are available for BKPyV viruria screening: urine cytopathology (“decoy cells”), DNA detection/quantification, and electronic microscopy “Haufen” bodies.<sup>26</sup>

Decoy cells are epithelial cells with enlarged nuclei and large basophilic ground-glass intranuclear inclusions.<sup>9</sup> Although one decoy cell is sufficient to mark the activation of polyomaviruses, in clinical practice an arbitrary threshold level of more than 10 decoy cells per liquid-based cytology preparation has been set to distinguish ‘decoy positive’ from ‘decoy negative’ patients.<sup>14</sup> Decoy cell can be easily detected in standard Papanicolaou-stained cytology preparations and is considered a cost-saving technique without the cross-contamination risks of PCR-based methodologies.<sup>22</sup> Also the NPV of decoy cells approximates 100%.<sup>26</sup> On the other hand, the PPV of decoy cell analysis to predict BKVN is only 25 to 30%; cytology results are more susceptible to delays in processing and shipment of samples; and require a trained cytologist.<sup>15</sup> Nevertheless, due to its high cost-effectiveness, the use of decoy cell remains solid in several diagnostic centers.

Electronic microscopy methods are based on the detection of viral particles or “Haufen”, defined as discrete, tightly clustered, cast-like aggregates of a minimum of six polyomaviruses with an unequivocal three-dimensional architecture.<sup>27</sup> Positive and negative predictive values of Haufen for BKVN are very high, reaching > 90%,<sup>26</sup> and may serve as a noninvasive means to diagnose BKVN in the urine.<sup>28</sup> However, the costs required to perform routine electronic microscopy is prohibitive for most diagnostic centers.

PCR-based methodologies for DNA detection/quantification in urine or blood have been considered the method of choice by current guidelines. Quantitative PCR (qPCR) is equivalent to decoy cytology to estimate BKPyV viruria and viral loads > 7 log<sub>10</sub> copies/ml are considered significant.<sup>26</sup> The advantages of testing BKPyV viruria are similar to decoy: high NPV for BKVN; precedes viremia ≥ 4 weeks,<sup>24</sup> which works as a warning sign to viremia; and is a non-invasive technique. In addition, BKVN

with detectable viruria without viremia has been reported.<sup>23</sup> Nonetheless, factors such as low PPV for BKVN, costs involved in qPCR, lack of standardization and natural fluctuation of BKPyV loads in urine, can be considerable disadvantages.<sup>26</sup>

BKPyV viremia, on the other hand, is universally considered the single most important parameter to predict BKVN,<sup>10,23,26</sup> reaching a PPV ≥ 90% and a sensitivity of 93% in persistently high BKV DNA loads (> 10<sup>4</sup> copies/ml). However, a viral load < 4 log<sub>10</sub> copies/ml does not completely rule out BKVN, and deserves continuous monitoring.<sup>28</sup> The optimal threshold of BKPyV DNAemia is not standardized, and values expressed in copies/ml > 500;<sup>28</sup> > 600;<sup>22</sup> > 750;<sup>29</sup> and > 1,000,<sup>30</sup> have been considered significant. Given its overall performance, BKPyV viremia testing without urine became the method of choice in many diagnostic centers and also recommended by the KDIGO Transplant Work Group in 2009,<sup>31</sup> although viruria screening prior to viremia quantitation is considered cost-saving.<sup>22</sup>

## CURRENT STRATEGIES FOR DIAGNOSIS AND MONITORING OF BKPYV INFECTION

BKVN is predominant (> 90%) in the first two years of transplantation, especially in the first trimester.<sup>24</sup> Screening efforts have mainly been focusing on the first 6-12 months. However, due to the precocity of BKPyV viremia in most cases, the tendency has been driven for condensed screening in the first months.

Current screening strategies relies on two basic principles: 1) viruria followed by viremia; 2) viremia only. Despite methodological variations, both strategies showed to be equally effective in detecting BKPyV infection, allowing for timely intervention.

### STRATEGY 1: VIRURIA FOLLOWED BY VIREMIA

As previously mentioned, viruria can be assessed by electronic microscopy, decoy cytology and qPCR. However, performing these techniques simultaneously seems do not add useful clinical information.<sup>30</sup> Current strategies indicate that viruria testing should be performed biweekly during the first three months. After, it will be performed monthly until the sixth month. Then, every 2 or 3 months until 2 years post-transplant, and anytime during any allograft dysfunction.<sup>11,22,26</sup> Nevertheless, monthly or quarterly (less frequent) screening up to 2 years post-transplant is still employed for urine BKPyV

search.<sup>10</sup> Decoy cell cytology and qPCR are the most used procedures, although cost-effectiveness favors the former.<sup>22</sup> Despite the low clinical significance of isolated viruria, the maintenance of high BKPyV loads in urine ( $> 7 \log_{10}$  copies/ml) or sustained decoy positivity (defined as  $\geq 2$  positive samples  $> 2$  weeks apart) is a strong indicative of future viremia (75%) and BKVN. Quantitative measurement of viremia is not indicated in patients without viruria.<sup>30</sup> However, in case of positive detection of BKPyV in urine by the aforesaid procedures, viremia testing should be performed.

#### STRATEGY 2: VIREMIA SCREENING

The guidelines suggest reducing immunosuppressive medications when BKPyV plasma is persistently greater than 10,000 copies/ml,<sup>30</sup> and the diagnosis of “presumptive BKVAN” should be made.<sup>12</sup> Most of the current BKPyV screening procedures are focused on viremia only, without the support of viruria. In both cases immunosuppression reduction is recommended even in the absence of BKPyV in biopsy (see ref. 26 for details). The term “sustained” or “persistent” is defined as two or more consecutive positive plasma samples (over  $\geq 2$ -3 weeks). However, different groups also recommend immunosuppression reduction after sustained<sup>21,29</sup> or a single low level ( $\approx 1,000$  copies/ml) viremia.<sup>24,28</sup> Monthly testing in the first 6-12 months followed by three months intervals is being widely adopted.

#### CLINICAL MANAGEMENT

Currently, reduction of immunosuppression is the keystone of therapy for BKVN. Since late diagnosis of BKVN is usually associated with an irreversible decline of graft function<sup>32,33</sup> and most of patients with viremia will eventually develop BKVN, regular screening for BKPyV reactivation, mainly during the first 2 years posttransplant, with subsequent pre-emptive reduction of immunosuppression is the usual procedure adopted by transplant centers.<sup>21-30</sup> Successful clearance or reduction of viremia is achieved in more than 80% of patients after 4 to 6 months.<sup>34,35</sup> Viremia should be continuously monitored every 2 to 4 weeks along with the levels of serum creatinine after reducing immunosuppression.<sup>31</sup>

When viremia is detected, a graft biopsy is usually indicated before reducing immunosuppression, mainly in case of renal function deterioration, to

distinct BKVN from rejection. Even if kidney function is unchanged, biopsy should be considered for those patients at a higher immunological risk in order to exclude a sub-clinical rejection episode.<sup>26</sup>

There is no clear evidence to support any specific modification of the immunosuppressive therapy. However, *in vitro* analyses suggest that reduction or withdrawn of calcineurin inhibitors should be the first step in immunosuppression modification due to its effects on T cells.<sup>36</sup> Reduction or withdrawn of anti-proliferative drugs, mainly mycophenolate, is also an usual target for changing immunosuppressive regimen.<sup>34</sup> On the other hand, *in vitro* analysis demonstrated a favorable action of mTOR inhibitors on BKVN progression.<sup>37</sup> Thus, despite the lack of controlled studies, it seems reasonable, at least for patients with a lower risk of rejection, the strategy of withdrawn or reducing tacrolimus and mycophenolate by approximately 25% to 50%,<sup>26</sup> meanwhile it might be considered to introduce mTOR inhibitors to the immunosuppressive regimen. After reduction of immunosuppression, renal function should be closely monitored due to the risk of rejection.

While reducing immunosuppression is a logical first line therapy, a second line option is not well defined. For these patients who fail to decrease viremia after reduction of immunosuppression, the use of immunoglobulin, cidofovir and fluoroquinolone has been attempted despite unclear benefits. Among those options, the use of fluoroquinolones was more extensively studied. *In vitro* analyses have shown that fluoroquinolones could have antiviral properties by inhibiting BKV replication.<sup>38</sup> Retrospective studies suggested that fluoroquinolones, used as pneumocystis prophylaxis, were effective at preventing BKPyV viremia after HSCT and kidney transplant.<sup>39,40</sup> However, a recent randomized clinical trial failed to show any benefit of fluoroquinolones in kidney transplant recipients with BKPyV viremia.<sup>35</sup>

Cidofovir is a nucleotide analogue of cytosine which acts on viral DNA and is usually used in the treatment of CMV complications in HIV patients. Benefits of cidofovir in patients with BKVN were described only in small non-controlled studies.<sup>41,42</sup> Due to its nephrotoxicity, cidofovir should be considered for treatment of BKVN only when other options have failed.



Intravenous immunoglobulin administration for the treatment of BKVN is an attractive idea since BKPyV is ubiquitous in human population. Thus, it is expected that immunoglobulin contains antibodies against this virus. The use of immunoglobulin seems especially attracting when the diagnosis of allograft rejection cannot be ruled out. In this case, the use of massive dose of immunoglobulin could be useful for both rejection and BKVN. However, there is a paucity of studies addressing the use of immunoglobulin in the treatment BKVN<sup>43-45</sup> and randomized clinical trials are needed.

Repeat transplantation is a feasible option after graft loss due to BKVN. A study of 126 patients who underwent repeat kidney transplantation after graft loss due to BKVN showed a 3-year graft survival rate of 93.6%.<sup>46</sup> In another study, 11 out of 31 patients presented post-transplant BKPyV viremia but with only two of them experiencing BKVN. Viremia clearance after BKVN in the initial transplant was significantly associated with a lower risk of recurrence after repeat transplantation.<sup>47</sup> The post-transplant management should follow the screening and follow-up previously described but always having in mind the narrow limits between excessive immunosuppression, with risk of reactivation of BKPyV viremia, and a loose immunosuppressive regimen for a patient already sensitized by the previous transplant.

## CONCLUSIONS

The advent of newer, more potent immunosuppressive agents may contribute to an apparently increasing incidence of BKVN in kidney transplant recipients. The optimal screening method and timing to detect BKPyV remains to be determined and cutoff values, especially for quantitative tests, need to be defined and standardized. Currently, early diagnosis and reduction of immunosuppression therapy seems to be the most efficacious treatment for BKPyV infection.

## REFERENCES

- Eash S, Manley K, Gasparovic M, Querbes W, Atwood WJ. The human polyomaviruses. *Cell Mol Life Sci* 2006;63:865-76. PMID: 16501889 DOI: <http://dx.doi.org/10.1007/s00018-005-5454-z>
- Krumbholz A, Bininda-Emonds OR, Wutzler P, Zell R. Phylogenetics, evolution, and medical importance of polyomaviruses. *Infect Genet Evol* 2009;9:784-99. DOI: <http://dx.doi.org/10.1016/j.meegid.2009.04.008>
- van Aalderen MC, Heutink KM, Huisman C, ten Berge IJ. BK virus infection in transplant recipients: clinical manifestations, treatment options and the immune response. *Neth J Med* 2012;70:172-83. PMID: 22641625
- Yogo Y, Sugimoto C, Zhong S, Homma Y. Evolution of the BK polyomavirus: epidemiological, anthropological and clinical implications. *Rev Med Virol* 2009;19:185-99. DOI: <http://dx.doi.org/10.1002/rmv.613>
- Zhong S, Randhawa PS, Ikegaya H, Chen Q, Zheng HY, Suzuki M, et al. Distribution patterns of BK polyomavirus (BKV) subtypes and subgroups in American, European and Asian populations suggest co-migration of BKV and the human race. *J Gen Virol* 2009;90:144-52. PMID: 19088283 DOI: <http://dx.doi.org/10.1099/vir.0.83611-0>
- White MK, Gordon J, Khalili K. The rapidly expanding family of human polyomaviruses: recent developments in understanding their life cycle and role in human pathology. *PLoS Pathog* 2013;9:e1003206. DOI: <http://dx.doi.org/10.1371/journal.ppat.1003206>
- Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. *J Med Virol* 2003;71:115-23. PMID: 12858417 DOI: <http://dx.doi.org/10.1002/jmv.10450>
- Jiang M, Abend JR, Johnson SF, Imperiale MJ. The role of polyomaviruses in human disease. *Virology* 2009;20:266-73. DOI: <http://dx.doi.org/10.1016/j.virol.2008.09.027>
- Nickeleit V, Hirsch HH, Zeiler M, Gudat F, Prince O, Thiel G, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. *Nephrol Dial Transplant* 2000;15:324-32. DOI: <http://dx.doi.org/10.1093/ndt/15.3.324>
- Dharmidharka VR, Abdunour HA, Araya CE. The BK virus in renal transplant recipients-review of pathogenesis, diagnosis, and treatment. *Pediatr Nephrol* 2011;26:1763-74. DOI: <http://dx.doi.org/10.1007/s00467-010-1716-6>
- Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. *Clin J Am Soc Nephrol* 2007;2:S36-46. DOI: <http://dx.doi.org/10.2215/CJN.00920207>
- Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. *Transplantation* 2005;79:1277-86. PMID: 15912088 DOI: <http://dx.doi.org/10.1097/01.TP.0000156165.83160.09>
- Drachenberg CB, Hirsch HH, Ramos E, Papadimitriou JC. Polyomavirus disease in renal transplantation: review of pathological findings and diagnostic methods. *Hum Pathol* 2005;36:1245-55. PMID: 16311117
- Nickeleit V, Mihatsch MJ. Polyomavirus nephropathy in native kidneys and renal allografts: an update on an escalating threat. *Transpl Int* 2006;19:960-73. DOI: <http://dx.doi.org/10.1111/j.1432-2277.2006.00360.x>
- Zalona AC, Varella RB, Takiya CM, Goncalves RT, Zalis MG, Santoro-Lopes G. A qualitative seminested PCR assay as an alternative to urine cytology for BK polyomavirus screening after renal transplantation. *Intervirology* 2013;56:249-52. DOI: <http://dx.doi.org/10.1159/000349896>
- Drachenberg CB, Hirsch HH, Papadimitriou JC, Gosert R, Wali RK, Munivenkatappa R, et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. *Transplantation* 2007;84:323-30. PMID: 17700156 DOI: <http://dx.doi.org/10.1097/01.tp.0000269706.59977.a5>
- Kwak EJ, Vilchez RA, Randhawa P, Shapiro R, Butel JS, Kusne S. Pathogenesis and management of polyomavirus infection in transplant recipients. *Clin Infect Dis* 2002;35:1081-7. PMID: 12384842 DOI: <http://dx.doi.org/10.1086/344060>
- Dalianis T, Hirsch HH. Human polyomaviruses in disease and cancer. *Virology* 2013;437:63-72. DOI: <http://dx.doi.org/10.1016/j.virol.2012.12.015>
- Moens U, Ludvigsen M, Van Ghelue M. Human polyomaviruses in skin diseases. *Patholog Res Int* 2011;2011:123491. PMID: 21941687
- DeCaprio JA, Garcea RL. A cornucopia of human polyomaviruses. *Nat Rev Microbiol* 2013;11:264-76. DOI: <http://dx.doi.org/10.1038/nrmicro2992>

21. Renoult E, Coutlée F, Pâquet M, St Louis G, Girardin C, Fortin MC, et al. Evaluation of a preemptive strategy for BK polyomavirus-associated nephropathy based on prospective monitoring of BK viremia: a kidney transplantation center experience. *Transplant Proc* 2010;42:4083-7. PMID: 21168633 DOI: <http://dx.doi.org/10.1016/j.transproceed.2010.09.024>
22. Chakera A, Dyar OJ, Hughes E, Bennett S, Hughes D, Roberts IS. Detection of polyomavirus BK reactivation after renal transplantation using an intensive decoy cell surveillance program is cost-effective. *Transplantation* 2011;92:1018-23. PMID: 21946172
23. Laskin BL, Goebel J. Cost-efficient screening for BK virus in pediatric kidney transplantation: a single-center experience and review of the literature. *Pediatr Transplant* 2010;14:589-95. DOI: <http://dx.doi.org/10.1111/j.1399-3046.2010.01318.x>
24. Alméras C, Vetromile F, Garrigue V, Szwarc I, Foulongne V, Mourad G. Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients. *Transpl Infect Dis* 2011;13:101-8. DOI: <http://dx.doi.org/10.1111/j.1399-3062.2011.00619.x>
25. Drachenberg CB, Papadimitriou JC, Ramos E. Histologic versus molecular diagnosis of BK polyomavirus-associated nephropathy: a shifting paradigm? *Clin J Am Soc Nephrol* 2006;1:374-9.
26. Hirsch HH, Randhawa P; AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. *Am J Transplant* 2013;13:179-88. DOI: <http://dx.doi.org/10.1111/ajt.12110>
27. Singh HK, Andreoni KA, Madden V, True K, Detwiler R, Weck K, et al. Presence of urinary Haufen accurately predicts polyomavirus nephropathy. *J Am Soc Nephrol* 2009;20:416-27. DOI: <http://dx.doi.org/10.1681/ASN.2008010117>
28. Westervelt JD, Alexander BD, Costa SF, Miller SE, Howell DN, Smith SR. Detection of BK polyomavirus after kidney transplantation: a comparison of urine electron microscopy with plasma polymerase chain reaction. *Clin Transplant* 2013;27:E42-8. DOI: <http://dx.doi.org/10.1111/ctr.12048>
29. Knight RJ, Gaber LW, Patel SJ, DeVos JM, Moore LW, Gaber AO. Screening for BK viremia reduces but does not eliminate the risk of BK nephropathy: a single-center retrospective analysis. *Transplantation* 2013;95:949-54. DOI: <http://dx.doi.org/10.1097/TP.0b013e31828423cd>
30. Drachenberg C, Hirsch HH, Papadimitriou JC, Mozafari P, Wali R, McKinney JD, et al. Cost efficiency in the prospective diagnosis and follow-up of polyomavirus allograft nephropathy. *Transplant Proc* 2004;36:3028-31. PMID: 15686687 DOI: <http://dx.doi.org/10.1016/j.transproceed.2004.10.045>
31. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant* 2009;9:S1-155.
32. Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. *N Engl J Med* 2002;347:488-96. PMID: 12181403 DOI: <http://dx.doi.org/10.1056/NEJMoa020439>
33. Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. *Kidney Int* 2005;68:1834-9. PMID: 16164661 DOI: <http://dx.doi.org/10.1111/j.1523-1755.2005.00602.x>
34. Schaub S, Hirsch HH, Dickenmann M, Steiger J, Mihatsch MJ, Hopfer H, et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. *Am J Transplant* 2010;10:2615-23. DOI: <http://dx.doi.org/10.1111/j.1600-6143.2010.03310.x>
35. Lee BT, Gabardi S, Grafals M, Hofmann RM, Akalin E, Aljanabi A, et al. Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial. *Clin J Am Soc Nephrol* 2014;9:583-9. DOI: <http://dx.doi.org/10.2215/CJN.04230413>
36. Egli A, Köhli S, Dickenmann M, Hirsch HH. Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. *Transplantation* 2009;88:1161-8. PMID: 19935369 DOI: <http://dx.doi.org/10.1097/TP.0b013e3181bca422>
37. Wali RK, Drachenberg C, Hirsch HH, Papadimitriou J, Nahar A, Mohanlal V, et al. BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. *Transplantation* 2004;78:1069-73. PMID: 15480176 DOI: <http://dx.doi.org/10.1097/01.TP.0000142127.84497.50>
38. Sharma BN, Li R, Bernhoff E, Gutteberg TJ, Rinaldo CH. Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. *Antiviral Res* 2011;92:115-23. PMID: 21798289 DOI: <http://dx.doi.org/10.1016/j.antiviral.2011.07.012>
39. Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. *Clin Infect Dis* 2005;40:528-37. PMID: 15712075 DOI: <http://dx.doi.org/10.1086/427291>
40. Gabardi S, Waikar SS, Martin S, Roberts K, Chen J, Borgi L, Sheashaa H, et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. *Clin J Am Soc Nephrol* 2010;5:1298-304. DOI: <http://dx.doi.org/10.2215/CJN.08261109>
41. Cabello V, Margarit N, Díaz Pedrero M, Bernal G, Pereira P, Gentil MA. Treatment of BK virus-associated nephropathy with Cidofovir in renal transplantation. *Transplant Proc* 2008;40:2930-2. PMID: 19010151 DOI: <http://dx.doi.org/10.1016/j.transproceed.2008.09.002>
42. Kadambi PV, Josephson MA, Williams J, Corey L, Jerome KR, Meehan SM, et al. Treatment of refractory BK virus-associated nephropathy with cidofovir. *Am J Transplant* 2003;3:186-91. DOI: <http://dx.doi.org/10.1034/j.1600-6143.2003.30202.x>
43. Sener A, House AA, Jevnikar AM, Boudville N, McAlister VC, Muirhead N, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. *Transplantation* 2006;81:117-20. PMID: 16421486 DOI: <http://dx.doi.org/10.1097/01.tp.0000181096.14257.c2>
44. Sharma AP, Moussa M, Casier S, Rehman F, Filler G, Grimmer J. Intravenous immunoglobulin as rescue therapy for BK virus nephropathy. *Pediatr Transplant* 2009;13:123-9. DOI: <http://dx.doi.org/10.1111/j.1399-3046.2008.00958.x>
45. Anyaegbu EI, Almond PS, Milligan T, Allen WR, Gharaybeh S, Al-Akash SI. Intravenous immunoglobulin therapy in the treatment of BK viremia and nephropathy in pediatric renal transplant recipients. *Pediatr Transplant* 2012;16:E19-24. DOI: <http://dx.doi.org/10.1111/j.1399-3046.2010.01384.x>
46. Dharnidharka VR, Cherikh WS, Neff R, Cheng Y, Abbott KC. Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis. *Am J Transplant* 2010;10:1312-5. DOI: <http://dx.doi.org/10.1111/j.1600-6143.2010.03083.x>
47. Geetha D, Sozio SM, Ghanta M, Josephson M, Shapiro R, Dadhania D, et al. Results of repeat renal transplantation after graft loss from BK virus nephropathy. *Transplantation* 2011;92:781-6. PMID: 21836535 DOI: <http://dx.doi.org/10.1097/TP.0b013e31822d08c1>